REGISTER
Prof.Tycel Jovelle Phillips at ASCO 2026: Key Advances in Lymphoma Immunotherapy
Dr. Phillips discusses which variables, including lymphoma subtype, prior therapy, tumor burden, patient fitness, and treatment accessibility, should guide sequencing decisions.

Dr. Tycel Jovelle Phillips, MD, Associate Professor, Division of Lymphoma, City of Hope National Medical Center

Relapsed lymphoma now offers multiple immunotherapy options, and choosing among CAR-T, bispecific antibodies, and ADCs requires patient-specific clinical judgment. Dr. Phillips discusses which variables, including lymphoma subtype, prior therapy, tumor burden, patient fitness, and treatment accessibility, should guide sequencing decisions. He also examines the collaboration infrastructure needed as these therapies expand from specialized academic centers into community practice, and shares his reflections on the advances presented at ASCO 2026.

0
0
Loading